Cargando…

Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation

Despite pharmacological advances such as lenvatinib approval, therapeutic failure of hepatocellular carcinoma (HCC) remains a big challenge due to the complexity of its underlying molecular mechanisms. Neuropilin-1 (NRP1) is a co-receptor involved in several cellular processes associated to chemores...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández-Palanca, Paula, Payo-Serafín, Tania, San-Miguel, Beatriz, Méndez-Blanco, Carolina, Tuñón, María J., González-Gallego, Javier, Mauriz, José L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10104874/
https://www.ncbi.nlm.nih.gov/pubmed/36376373
http://dx.doi.org/10.1038/s41401-022-01021-2
_version_ 1785026128011853824
author Fernández-Palanca, Paula
Payo-Serafín, Tania
San-Miguel, Beatriz
Méndez-Blanco, Carolina
Tuñón, María J.
González-Gallego, Javier
Mauriz, José L.
author_facet Fernández-Palanca, Paula
Payo-Serafín, Tania
San-Miguel, Beatriz
Méndez-Blanco, Carolina
Tuñón, María J.
González-Gallego, Javier
Mauriz, José L.
author_sort Fernández-Palanca, Paula
collection PubMed
description Despite pharmacological advances such as lenvatinib approval, therapeutic failure of hepatocellular carcinoma (HCC) remains a big challenge due to the complexity of its underlying molecular mechanisms. Neuropilin-1 (NRP1) is a co-receptor involved in several cellular processes associated to chemoresistance development. Since both the double-edged process of autophagy and hypoxia-derived response play crucial roles in the loss of therapeutic effectiveness, herein we investigated the interplay among NRP1, autophagy and hypoxia in development of lenvatinib resistance in HCC cell lines. We first analyzed NRP1 expression levels in human HCC samples from public databases, found significantly increased NRP1 expression in human HCC samples as well as its correlation with advanced tumor and metastasis stages. Among 3 HCC cell lines (HepG2, Huh-7 and Hep3B), Hep3B and Huh-7 cells showed significantly increased NRP1 expression levels and cell migration ability together with higher susceptibility to lenvatinib. We demonstrated that NRP1 gene silencing significantly enhanced the anticancer effects of lenvatinib on Hep3B and Huh-7 cells. Furthermore, lenvatinib suppressed NRP1 expression through promoting autophagy in Hep3B and Huh-7 cells; co-treatment with bafilomycin A1 attenuated the antitumor effects of lenvatinib, and NRP1 silencing prevented this loss of in vitro effectiveness of lenvatinib even in the presence of bafilomycin A1. In addition, exposure to a hypoxic microenvironment significantly decreased NRP1 expression through autophagy in Hep3B and Huh-7 cells. Under hypoxia, HIF-1α directly modulated NRP1 expression; HIF-1α silencing not only enhanced the anticancer effects of combined lenvatinib and hypoxia, but also prevented the loss of effectiveness caused by bafilomycin A1, highlighting the potential role of HIF-1α-derived hypoxia response in the adaptive cellular response to lenvatinib and promoting resistance acquisition by autophagy modulation. Overall, NRP1 may constitute a potential therapeutic target to prevent lenvatinib failure derived from a hypoxia-associated modulation of autophagy in advanced HCC.
format Online
Article
Text
id pubmed-10104874
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-101048742023-04-16 Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation Fernández-Palanca, Paula Payo-Serafín, Tania San-Miguel, Beatriz Méndez-Blanco, Carolina Tuñón, María J. González-Gallego, Javier Mauriz, José L. Acta Pharmacol Sin Article Despite pharmacological advances such as lenvatinib approval, therapeutic failure of hepatocellular carcinoma (HCC) remains a big challenge due to the complexity of its underlying molecular mechanisms. Neuropilin-1 (NRP1) is a co-receptor involved in several cellular processes associated to chemoresistance development. Since both the double-edged process of autophagy and hypoxia-derived response play crucial roles in the loss of therapeutic effectiveness, herein we investigated the interplay among NRP1, autophagy and hypoxia in development of lenvatinib resistance in HCC cell lines. We first analyzed NRP1 expression levels in human HCC samples from public databases, found significantly increased NRP1 expression in human HCC samples as well as its correlation with advanced tumor and metastasis stages. Among 3 HCC cell lines (HepG2, Huh-7 and Hep3B), Hep3B and Huh-7 cells showed significantly increased NRP1 expression levels and cell migration ability together with higher susceptibility to lenvatinib. We demonstrated that NRP1 gene silencing significantly enhanced the anticancer effects of lenvatinib on Hep3B and Huh-7 cells. Furthermore, lenvatinib suppressed NRP1 expression through promoting autophagy in Hep3B and Huh-7 cells; co-treatment with bafilomycin A1 attenuated the antitumor effects of lenvatinib, and NRP1 silencing prevented this loss of in vitro effectiveness of lenvatinib even in the presence of bafilomycin A1. In addition, exposure to a hypoxic microenvironment significantly decreased NRP1 expression through autophagy in Hep3B and Huh-7 cells. Under hypoxia, HIF-1α directly modulated NRP1 expression; HIF-1α silencing not only enhanced the anticancer effects of combined lenvatinib and hypoxia, but also prevented the loss of effectiveness caused by bafilomycin A1, highlighting the potential role of HIF-1α-derived hypoxia response in the adaptive cellular response to lenvatinib and promoting resistance acquisition by autophagy modulation. Overall, NRP1 may constitute a potential therapeutic target to prevent lenvatinib failure derived from a hypoxia-associated modulation of autophagy in advanced HCC. Springer Nature Singapore 2022-11-14 2023-05 /pmc/articles/PMC10104874/ /pubmed/36376373 http://dx.doi.org/10.1038/s41401-022-01021-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Fernández-Palanca, Paula
Payo-Serafín, Tania
San-Miguel, Beatriz
Méndez-Blanco, Carolina
Tuñón, María J.
González-Gallego, Javier
Mauriz, José L.
Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation
title Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation
title_full Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation
title_fullStr Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation
title_full_unstemmed Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation
title_short Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation
title_sort hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10104874/
https://www.ncbi.nlm.nih.gov/pubmed/36376373
http://dx.doi.org/10.1038/s41401-022-01021-2
work_keys_str_mv AT fernandezpalancapaula hepatocellularcarcinomacellslosslenvatinibefficacyinvitrothroughautophagyandhypoxiaresponsederivedneuropilin1degradation
AT payoserafintania hepatocellularcarcinomacellslosslenvatinibefficacyinvitrothroughautophagyandhypoxiaresponsederivedneuropilin1degradation
AT sanmiguelbeatriz hepatocellularcarcinomacellslosslenvatinibefficacyinvitrothroughautophagyandhypoxiaresponsederivedneuropilin1degradation
AT mendezblancocarolina hepatocellularcarcinomacellslosslenvatinibefficacyinvitrothroughautophagyandhypoxiaresponsederivedneuropilin1degradation
AT tunonmariaj hepatocellularcarcinomacellslosslenvatinibefficacyinvitrothroughautophagyandhypoxiaresponsederivedneuropilin1degradation
AT gonzalezgallegojavier hepatocellularcarcinomacellslosslenvatinibefficacyinvitrothroughautophagyandhypoxiaresponsederivedneuropilin1degradation
AT maurizjosel hepatocellularcarcinomacellslosslenvatinibefficacyinvitrothroughautophagyandhypoxiaresponsederivedneuropilin1degradation